These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38608709)

  • 1. The enchanting canvas of CAR technology: Unveiling its wonders in non-neoplastic diseases.
    Shu J; Xie W; Chen Z; Offringa R; Hu Y; Mei H
    Med; 2024 Jun; 5(6):495-529. PubMed ID: 38608709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of CAR-NK Cells Targeting cSCC-Specific Antigens for Precision Immunotherapy.
    Tayanloo-Beik A; Roudsari PP; Aghayan H; Arjmand R; Rezaei-Tavirani M; Larijani B; Rajaeinejad M; Mosaed R; Arjmand B
    Methods Mol Biol; 2024; 2849():253-263. PubMed ID: 38095836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T cells: Building on the CD19 paradigm.
    Globerson Levin A; Rivière I; Eshhar Z; Sadelain M
    Eur J Immunol; 2021 Sep; 51(9):2151-2163. PubMed ID: 34196410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases.
    Hassan SH; Alshahrani MY; Saleh RO; Mohammed BA; Kumar A; Almalki SG; Alkhafaji AT; Ghildiyal P; Al-Tameemi AR; Elawady A
    Med Oncol; 2024 Apr; 41(6):127. PubMed ID: 38656354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR-NK cell in cancer immunotherapy; A promising frontier.
    Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
    Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects.
    Zhang PF; Xie D; Li Q
    Immunotherapy; 2020 Sep; 12(13):1021-1034. PubMed ID: 32727249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner.
    Etxebeste-Mitxeltorena M; Del Rincón-Loza I; Martín-Antonio B
    Front Immunol; 2021; 12():717850. PubMed ID: 34447383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
    Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
    Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E
    Front Immunol; 2020; 11():581468. PubMed ID: 33193388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding the role of CAR T-cell therapy: From B-cell hematological malignancies to autoimmune rheumatic diseases.
    Shumnalieva R; Velikova T; Monov S
    Int J Rheum Dis; 2024 May; 27(5):e15182. PubMed ID: 38742463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical development of natural killer cells expressing chimeric antigen receptors.
    Golden RJ; Fesnak AD
    Transfus Apher Sci; 2021 Feb; 60(1):103065. PubMed ID: 33468407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
    Mehta RS; Rezvani K
    Front Immunol; 2018; 9():283. PubMed ID: 29497427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
    Yilmaz A; Cui H; Caligiuri MA; Yu J
    J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR macrophages tuning the immune symphony of anti-cancer therapies.
    Paasch D; Lachmann N
    Cell Stem Cell; 2024 Jun; 31(6):791-793. PubMed ID: 38848684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highlight of 2023: CAR T cells driving precision therapy for autoimmune disease.
    Lee AY; Reed JH
    Immunol Cell Biol; 2024 Jul; 102(6):437-440. PubMed ID: 38693765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is There a Place for Chimeric Antigen Receptor-T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases?
    Orvain C; Boulch M; Bousso P; Allanore Y; Avouac J
    Arthritis Rheumatol; 2021 Nov; 73(11):1954-1965. PubMed ID: 34042325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.
    Zhao Y; Zhou X
    Immunotherapy; 2020 Jun; 12(9):653-664. PubMed ID: 32436428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease.
    Daamen AR; Lipsky PE
    Ann Rheum Dis; 2024 May; 83(6):696-699. PubMed ID: 38637134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.